Abstract
Disruption of the breast cancer susceptibility gene BRCA2 is associated with increased risk of developing breast and ovarian cancer. Over 1800 sequence changes in BRCA2 have been reported, although for many the pathogenicity is unclear. Classifying these changes remains a challenge, as they may disrupt regulatory sequences as well as the primary protein coding sequence. Sequence changes located in the splice site consensus sequences often disrupt splicing, however sequence changes located within exons are also able to alter splicing patterns. Unfortunately, the presence of these exonic splicing enhancers (ESEs) and the functional effect of variants within ESEs it is currently difficult to predict. We have previously developed a method of predicting which sequence changes within exons are likely to affect splicing, using BRCA1 as an example. In this paper, we have predicted ESEs in BRCA2 using the web-based tool ESEfinder and incorporated the same series of filters (increased threshold, 125 nt limit and evolutionary conservation of the motif) in order to identify predicted ESEs that are more likely to be functional. Initially 1114 ESEs were predicted for BRCA2, however after all the filters were included, this figure was reduced to 31, 3% of the original number of predicted ESEs. Reported unclassified sequence variants in BRCA2 were found to colocalise to 55% (17/31) of these conserved ESEs, while polymorphisms colocalised to 0 of the conserved ESEs. In summary, we have identified a subset of unclassified sequence variants in BRCA2 that may adversely affect splicing and thereby contribute to BRCA2 disruption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BIC:
-
Breast cancer information core
- ESE:
-
Exonic splicing enhancer
- kConFab:
-
Kathleen Cunningham Consortium for Research into Familial Breast Cancer
- NCBI:
-
National Center for Biotechnology Information
- NMD:
-
Nonsense mediated decay
- NS:
-
Nonsense
- SR:
-
Serine/arginine rich
- UV:
-
Unclassified variant
References
Wong AK, Pero R, Ormonde PA et al (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272(51):31941–31944
Milner J, Ponder B, Hughes-Davies L et al (1997) Transcriptional activation functions in BRCA2. Nature 386(6627):772–773
Fuks F, Milner J, Kouzarides T (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17(19):2531–2534
Goldgar DE, Easton DF, Deffenbaugh AM et al (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75(4):535–544
Wu K, Hinson SR, Ohashi A et al (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65(2):417–426
Carvalho MA, Marsillac SM, Karchin R et al (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67(4):1494–1501
Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027
Duan J, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216
Liu HX, Cartegni L, Zhang MQ et al (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27(1):55–58
Fackenthal JD, Cartegni L, Krainer AR et al (2002) BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71(3):625–631
Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336
Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18(4):186–193
Blencowe BJ (2000) Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 25(3):106–110
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298
Claes K, Poppe B, Machackova E et al (2003) Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 37(3):314–320
Zatkova A, Messiaen L, Vandenbroucke I et al (2004) Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat 24(6):491–501
Pagenstecher C, Wehner M, Friedl W et al (2006) Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet 119(1–2):9–22
Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31(13):3568–3571
Gorlov IP, Gorlova OY, Frazier ML et al (2004) Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). Mutat Res 554(1–2):175–183
Pettigrew C, Wayte N, Lovelock PK et al (2005) Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Res 7(6):R929–R939
Majewski J, Ott J (2002) Distribution and characterization of regulatory elements in the human genome. Genome Res 12(12):1827–1836
Tavtigian SV, Deffenbaugh AM, Yin L et al (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43(4):295–305
Mathe E, Olivier M, Kato S et al (2006) Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5):1317–1325
Gorlov IP, Gorlova OY, Frazier ML et al (2003) Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. Am J Hum Genet 73(5):1157–1161
Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24(18):7987–7997
Courtois S, Verhaegh G, North S et al (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21(44):6722–6728
Orban TI, Olah E (2003) Emerging roles of BRCA1 alternative splicing. Mol Pathol 56(4):191–197
Graveley BR, Hertel KJ, Maniatis T (1998) A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J 17(22):6747–6756
Wu Y, Zhang Y, Zhang J (2005) Distribution of exonic splicing enhancer elements in human genes. Genomics 86(3):329–336
Acknowledgements
The authors wish to thank Sean Tavtigian, IARC, for advice regarding amino acid substitution analysis. This research was supported by the University of Queensland, The National Health and Medical Research Council of Australia (NHMRC) and the Susan G. Komen Breast Cancer Foundation. ABS is a recipient of an NHMRC Career Development Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pettigrew, C.A., Wayte, N., Wronski, A. et al. Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants. Breast Cancer Res Treat 110, 227–234 (2008). https://doi.org/10.1007/s10549-007-9714-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9714-5